Reversible severe mitral regurgitation during immunotherapy in a structurally vulnerable valve: a case report
Sachin Singh, Ushma Majmudar, Indu Poornima, Anita Radhakrishnan, Christoph Sinning, Ivan Wong, Deepti Ranganathan · 2026
Read Reversible severe mitral regurgitation during immunotherapy in a structurally vulnerable valve: a case report by Sachin Singh, Ushma Majmudar, Indu Poornima, Anita Radhakrishnan, Christoph Sinning, Ivan Wong, Deepti Ranganathan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13332506.txt.
Description
Sachin Singh and colleagues report a 2026 case in which leukemia immunotherapy briefly caused severe leaking of the mitral valve in a woman whose valve was already quietly vulnerable. She had taken the diet drug fenfluramine ten years earlier, a fact she disclosed only late.
The 48-year-old had B-cell acute lymphoblastic leukemia and only a trace of valve leakage at baseline. After her second blinatumomab cycle she developed acute heart failure. A repeat scan showed severe leakage with a restricted rear leaflet, without the body-wide inflammation or organ damage that drug reactions usually bring. The team held the drug, treated the heart failure, and the leak improved enough to restart therapy safely. They argue the drug's pressure shifts unmasked a fenfluramine-weakened valve, and that careful, non-judgmental history taking plus hemodynamic care can keep lifesaving treatment going.
Catalog record
| CREATOR | Sachin Singh, Ushma Majmudar, Indu Poornima, Anita Radhakrishnan, Christoph Sinning, Ivan Wong, Deepti Ranganathan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15948 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |